|
June. 30, 2021 |
|
|
July. 22, 2024 |
|
|
jRCT2071210039 |
The Comparative Pharmacokinetic Study of OP-2024 in Healthy Male Volunteers |
|
OP-2024-001 Study |
Taguchi Fumi |
||
OHARA Pharmaceutical Co.,Ltd. |
||
36F St.Luke's Tower 8-1, Akashi-cho, Chuo-ku, Tokyo, Japan |
||
+81-3-6740-7701 |
||
chiken@ohara-ch.co.jp |
||
Department of Clinical Development |
||
OHARA Pharmaceutical Co.,Ltd. |
||
36F St.Luke's Tower 8-1, Akashi-cho, Chuo-ku, Tokyo, Japan |
||
+81-3-6740-7701 |
||
chiken@ohara-ch.co.jp |
Complete |
July. 20, 2021 |
||
| July. 20, 2021 | ||
| 12 | ||
Interventional |
||
non-randomized controlled trial |
||
open(masking not used) |
||
active control |
||
crossover assignment |
||
other |
||
1) Healthy Japanese male. |
||
1) Those with a history of allergies to investigational drug ingredients, drugs, or foods |
||
| 20age old over | ||
| 40age old under | ||
Male |
||
Parkinson's disease |
||
Oral administration of OP-2024 (1 capsule) or control (1 tablet). |
||
Pharmacokinetics |
||
Safety |
||
| OHARA Pharmaceutical Co.,Ltd. |
| Hakata Clinic Institutional Review Board | |
| 6-18, Tenyamachi, Hakata-ku, Fukuoka-shi, Fukuoka | |
+81-92-283-7701 |
|
| Approval | |
June. 18, 2021 |
No |
none |